 OncLive | FDA Approves Everolimus (Afinitor) for Metastatic Breast Cancer Cancer Network The US Food and Drug Administration (FDA) approved the mTOR inhibitor everolimus (Afinitor) last week for use in postmenopausal women with HER2-negative, hormone-receptorāpositive advanced breast cancer patients. Afinitor was approved in ... FDA Approves Everolimus for Advanced Breast Cancer FDA approves Afinitor for Advanced Breast Cancer FDA Adds Afinitor to Treatments for Metastatic Breast Cancer |
